Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL

4 November 2026 · By · Wire by Fusion42

Published

4 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 4 November 2026 · Fusion42 review

The FDA has granted priority review to the supplemental new drug application for the combination of zanubrutinib and rituximab as a treatment for previously untreated mantle cell lymphoma (MCL).

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

FDA priority review speeds up access to a new combo therapy for untreated MCL, signalling faster market entry and a competitive window for biotech companies focused on oncology treatments.

◆ Coverage

1 source · 4 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfdapriority-reviewmantle-cell-lymphomazanubrutinibrituximabdrug-approval